Table 2

Serum levels of HMGB1 in 20 patients

Baseline

Follow-up

Patient

HMGB1

WHO

AI

CI

U-prot

Crea

HMGB1

WHO

AI

CI

U-prot

Crea

1

19.8

IV

8

0

0.0

66

34.1

I

0

0

0.0

78

2

84.8

IV

8

1

0.2

74

60.6

III

9

1

0.3

78

3

88.4

IV

12

1

1.9

185

89.6

IV

4

3

1.6

86

4

37.1

IV

9

1

3.7

89

27.9

II

2

0

0.9

86

5

29.6

III

5

0

1.3

77

40.3

V

1

2

1.6

87

6

87.9

IV

13

3

1.0

94

71.4

III

4

3

0.4

86

7

86.8

IV

6

0

2.1

64

29.3

II

1

1

3.4

60

8

98.1

IV

12

6

4.9

284

72.6

II

2

8

1.0

306

9

125.9

IV

6

2

1.5

167

109.8

II

1

6

0.1

72

10

120.4

IV

3

0

1.4

90

77.9

II

2

4

0.1

78

11

113.8

III

7

0

1.0

129

128.1

II

1

1

0.1

105

12

126.4

III/V

3

0

3.5

52

129.7

V

2

2

0.7

54

13

130

III

5

1

0.1

70

142.7

II

0

4

0.0

48

14

59.4

IV

6

1

0.3

82

61.7

IV

10

1

2.1

80

15

128.2

III

5

1

1.8

66

148.4

II

1

1

1.8

74

16

155

III

5

5

0.8

53

117.9

II

2

0

0.3

61

17

155.9

IV

5

0

4.8

96

145.9

V

1

0

0

74

18

159.9

III/V

4

0

0.2

53

181.5

V

1

0

0

68

19

158.9

III

5

0

0.3

52

159.9

III

3

1

0.1

66

20

202.4

III

5

1

1.1

60

183.9

III

4

1

0.5

68

Serum levels of high-mobility group box 1 protein (HMGB1) (expressed as nanograms per milliliter), histopathological findings, and renal activity at baseline and follow-up are shown. Creatinine (crea) is expressed as micromoles per liter. AI, activity index; CI, chronicity index, u-prot; 24-hour urine albumin excretion; WHO, World Health Organization.

Zickert et al. Arthritis Research & Therapy 2012 14:R36   doi:10.1186/ar3747